BioLineRx reported an earnings per share (EPS) of -0.38, matching the estimated EPS, and generated revenue of $514,000, surpassing the estimated revenue.The company is advancing its clinical pipeline with the upcoming Phase 1/2a clinical trial of GLIX1 for glioblastoma (GBM).Despite financial challenges, including a negative P/E ratio of approximately -3.24 and a debt-to-equity ratio of about 0.58, BioLineRx shows growth potential with a price-to-sales ratio of 0.84.BioLineRx Ltd. (NASDAQ:BLRX) is a biophar ...

BioLineRx (NasdaqCM:BLRX) Q4 2025 Earnings call March 23, 2026 08:30 AM ET Company ParticipantsElla Sorani - Chief Development OfficerIrina Koffler - Investor Relations OfficerMali Zeevi - CFOPhilip Serlin - CEOConference Call ParticipantsJoe Pantginis - Managing Director and Equity Research AnalystJohn Vandermosten - Senior AnalystJustin Walsh - AnalystOperatorLadies and gentlemen, thank you for standing by. Welcome to the BioLineRx fourth quarter and full year 2025 financial results conference call. All p ...

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [19] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [20] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [21] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [21] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][21] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue to the company [13] - The company continues to support the development of motixafortide in pancreatic cancer, with enrollment in the Chemo4METPANC trial accelerating [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an expected annual incidence of approximately 18,500 patients in the U.S. and 13,500 in the EU by 2030 [8] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma treatment, highlighting the lack of advancements in the standard of care since 2005 [7] - The company is well-positioned to drive innovation in challenging cancer types and is excited about future developments [57] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [17] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [28][29] Question: Enthusiasm from principal investigators for GLIX1 trial - There is significant enthusiasm from investigators regarding GLIX1's novel mechanism of action and preclinical results, with eagerness to initiate the study [39] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway, but no interim readouts expected due to the study's blinded nature [44][46] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the GLIX1 study are recurrent or progressed GBM patients, typically having exhausted standard care options [47] Question: Ayrmid's guidance on expected sales - Management indicated that Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [53]

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [18] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [19] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [20] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [20] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][20] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue for the company [12] - The company continues to support the development of motixafortide in pancreatic cancer, with a phase IIb clinical trial showing accelerated enrollment [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an annual incidence of approximately 18,500 patients in the U.S. and 13,500 in the EU [8] - The unmet need in glioblastoma treatment is significant, with current therapies showing limited advancements since 2005 [7] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma and other cancers, highlighting the enthusiasm from clinical investigators [38] - The company is well-positioned to drive innovation in challenging cancer types and is focused on maximizing the value of GLIX1 [56] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [16] - The company remains a lean organization following the shutdown of U.S. commercialization operations, concentrating on development [12] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [27][28] Question: Enthusiasm from principal investigators for GLIX1 trial - Investigators are highly enthusiastic about GLIX1 due to its novel mechanism and promising preclinical results [38] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway [44] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the study are recurrent or progressed GBM patients, having run out of standard care options [46] Question: Measurement of blood-brain barrier penetration in the study - While biopsies may be taken, the study is not designed to assess blood-brain barrier penetration as a primary measure [50] Question: Ayrmid's guidance on expected sales - Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [51]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 19 ...

BioLineRx Reports 2025 Financial Results and Provides Corporate Update Accessibility StatementSkip Navigation - On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms - Clinical UpdatesGLIX1 On track to initiate a Phase 1/2a clinical trial of GLIX1 in glioblastoma by the end of the month. - Management t ...

BioLineRx to Report 2025 Annual Results on March 23, 2026 Accessibility StatementSkip Navigation Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 16, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2025 on Monday, March 23, 2026, before the U.S. mark ...

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $0.4 million, reflecting royalties from Ayrmid for APHEXDA commercialization, a significant decrease compared to the previous year due to the upfront payment received under the Gloria license agreement in 2024 [17][18] - Research and development expenses decreased to $1.7 million from $2.6 million in Q3 2024, primarily due to lower expenses related to metixafortide and a reduction in headcount [18][19] - Net loss for Q3 2025 was $1 million, a substantial decrease from a net loss of $5.8 million in Q3 2024 [19] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $2.4 million in Q3 2025, resulting in $0.4 million of royalty revenue to the company [13][14] - The company continues to support the development of metixafortide in pancreatic cancer, with ongoing trials that could represent significant value inflection points [12][16] Market Data and Key Metrics Changes - The total addressable market for glioblastoma in the U.S. and Europe is estimated to exceed $3.7 billion, with an expected annual incidence of approximately 18,500 patients in the U.S. by 2030 [8][9] - The unmet need in glioblastoma treatment is significant, with current standard care established over 20 years ago and limited improvements since [7][8] Company Strategy and Development Direction - The company has established a joint venture with Hemispherian to develop GLIX1, a novel molecule targeting glioblastoma and other cancers, leveraging both companies' strengths [3][4] - The strategy includes expanding GLIX1's development into additional cancer indications once safety and dosing are established [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 and its unique mechanism of action, which could provide significant advancements in cancer treatment [9][10] - The company remains focused on creating long-term value for shareholders while addressing significant unmet medical needs in oncology [13][19] Other Important Information - The company ended Q3 2025 with cash and equivalents of approximately $25.2 million, sufficient to fund operations into the first half of 2027 [13][19] - A key patent for GLIX1 has been allowed, broadening its protection until at least 2040, with potential extensions [10][11] Q&A Session Summary Question: Insights on upcoming clinical study for GLIX1 and potential PD markers - Management confirmed plans to collect extensive pharmacokinetic data and mentioned challenges in obtaining pharmacodynamic markers due to the nature of the trial [22][23] Question: Intermediate manufacturing capacity needs for GLIX1 - The company stated that current manufacturing capacity is sufficient for Phase II-A trials, with no anticipated changes needed [25] Question: Timeline for preclinical data readouts for additional tumor indications - Management indicated that results from preclinical models are being performed, with plans to present findings at conferences next year [26] Question: Medium-term market penetration targets for APHEXDA - Management clarified that they cannot provide guidance on market penetration as they no longer own the asset in the territories held by Ayrmid [31] Question: Reasonable targets for overall survival improvement in GBM - Management noted that for newly diagnosed GBM, a median overall survival improvement of approximately two and a half months would be a benchmark for interest from established pharma [33] Question: Financial statement treatment of investments in the JV - Management confirmed that expenses related to the JV will be consolidated in their financial statements and reflected as R&D expenses [35][36]

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $0.4 million, reflecting royalties from ARAMID for Effexta commercialization, a significant decrease compared to the previous year due to the absence of upfront payments and direct sales [17][18] - Research and development expenses decreased to $1.7 million from $2.6 million in Q3 2024, primarily due to lower expenses related to metixafortide and a reduction in headcount [18][19] - Net loss for Q3 2025 was $1 million, a substantial improvement from a net loss of $5.8 million in Q3 2024 [19] Business Line Data and Key Metrics Changes - Effexta generated sales of $2.4 million in Q3 2025, resulting in $0.4 million of royalty revenue to the company [13][14] - The company continues to support the development of metixafortide in pancreatic cancer, with a phase 2b clinical trial ongoing [12] Market Data and Key Metrics Changes - The total addressable market for glioblastoma in the U.S. and Europe is estimated to exceed $3.7 billion, with an expected annual incidence of approximately 18,500 patients in the U.S. by 2030 [8] Company Strategy and Development Direction - The company established a joint venture with Hemispherian to develop GLIX1, a novel treatment for glioblastoma, leveraging both companies' strengths in clinical and regulatory success [3][4] - The company plans to initiate a phase 1/2a trial for GLIX1 in the first quarter of next year, with data anticipated in the first half of 2027 [5][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma treatment, highlighting the poor prognosis and limited advancements in current therapies [7][8] - The company remains focused on creating long-term value for shareholders while advancing innovative cancer treatments [13] Other Important Information - The company ended Q3 2025 with cash and equivalents of approximately $25.2 million, sufficient to fund operations into the first half of 2027 [19] - A new patent for GLIX1 broadens its protection until 2040, with potential extensions, enhancing its competitive position in the market [10][11] Q&A Session Summary Question: What potential pharmacodynamic markers will be released during the GLIX1 clinical study? - Management plans to collect extensive pharmacokinetic data and will utilize biopsies if surgeries occur during the trial to gather pharmacodynamic markers [22][23] Question: What are the intermediate manufacturing needs for GLIX1? - The current manufacturer has sufficient capacity for the needs of the phase II-A trial, with no anticipated changes [25] Question: When might preclinical data for additional tumor indications be available? - Results from preclinical models are being performed, with plans to present findings at conferences next year [26] Question: What is the medium-term target for market penetration of Effexta? - Management indicated they cannot provide guidance on market penetration as they no longer own the asset in the territories held by ARAMID [31] Question: What improvement in overall survival for GBM would attract interest from established pharma? - For newly diagnosed GBM, an improvement of approximately two and a half months in median overall survival would be significant [33] Question: How will investments in the joint venture appear on financial statements? - The joint venture will be consolidated in the financial statements, with all expenses reflected as research and development expenses [35][36]

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $0.4 million, reflecting royalties from ARAMID for Effexta commercialization, a significant decrease compared to the previous year due to the absence of upfront payments from Gloria Biosciences [17][18] - Research and development expenses decreased to $1.7 million from $2.6 million in Q3 2024, primarily due to lower expenses related to metixafortide and a reduction in headcount [18] - Net loss for Q3 2025 was $1 million, a substantial improvement from a net loss of $5.8 million in Q3 2024 [19] Business Line Data and Key Metrics Changes - Effexta generated sales of $2.4 million in Q3 2025, resulting in $0.4 million of royalty revenue to BioLineRx [13][14] - The company continues to support the development of metixafortide in pancreatic cancer, with a phase 2b clinical trial ongoing [12] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an expected annual incidence of approximately 18,500 patients in the U.S. by 2030 [8][9] Company Strategy and Development Direction - The establishment of a joint venture with Hemispherian aims to develop GlyxOne, a novel treatment for glioblastoma and other cancers, leveraging both companies' strengths [4][5] - The company plans to initiate a phase 1/2a glioblastoma trial in Q1 2026, with data anticipated in the first half of 2027 [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about GlyxOne's potential to address significant unmet needs in glioblastoma treatment, highlighting the poor prognosis and limited advancements in current therapies [6][7] - The company remains focused on creating long-term value for shareholders while advancing innovative cancer treatments [13] Other Important Information - The company ended Q3 2025 with cash and equivalents of approximately $25.2 million, sufficient to fund operations into the first half of 2027 [19] - GlyxOne has received a notice of allowance for a key patent, broadening its protection until at least 2040 [10][11] Q&A Session Summary Question: Insights on upcoming clinical study for GlyxOne - Management confirmed plans to collect extensive pharmacokinetic data and mentioned challenges in obtaining pharmacodynamic markers due to the nature of the study [22][23] Question: Medium-term market penetration targets for Effexta - Management stated they cannot provide guidance on market penetration as they no longer own the asset in the territories held by ARAMID [30] Question: Reasonable targets for overall survival improvement in GBM - Management indicated that for newly diagnosed GBM, a median overall survival improvement of approximately two and a half months would be a sufficient benchmark [31][32] Question: Financial statement treatment of JV investments - Management clarified that expenses related to the JV will be consolidated in their financial statements and reflected as R&D expenses [33][34]